



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>C07D 213/65, A61K 31/44</b>	<b>A1</b>	(11) International Publication Number: <b>WO 95/00487</b> (43) International Publication Date: <b>5 January 1995 (05.01.95)</b>
<p>(21) International Application Number: <b>PCT/EP94/02028</b></p> <p>(22) International Filing Date: <b>20 June 1994 (20.06.94)</b></p> <p>(30) Priority Data: <b>9313145.6</b>      <b>25 June 1993 (25.06.93)</b>      <b>GB</b></p> <p>(71) Applicant (for all designated States except US): <b>SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>SHELDRAKE, Peter, William [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). POWLING, Laurence, Charles [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). BICKLE, Peter, William [NZ/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB).</b></p> <p>(74) Agent: <b>THOMPSON, Clive, B.; Corporate Intellectual Property, SmithKline Beecham, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB).</b></p>	<p>(81) Designated States: <b>AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(54) Title: <b>PALLADIUM CATALYZED VINYLIC SUBSTITUTION REACTIONS WITH 2-SUBSTITUTED-PYRIDINES</b>		
<p>(57) Abstract</p> <p><b>An improved process for the preparation of substituted pyridine derivatives.</b></p>		

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

# PALLADIUM CATALYZED VINYLIC SUBSTITUTION REACTIONS WITH 2-SUBSTITUTED-PYRIDINES


The present invention relates to an improved process for the preparation of substituted pyridine derivatives. Substituted pyridine derivatives are disclosed in WO93/06085 as medicaments being useful for the treatment of various diseases such as psoriasis.

Various processes for the preparation of these medicaments are also disclosed in WO93/06085. In particular, 2-(trans-2-carboxymethylethenyl)-3-[8-(4-methoxyphenyl)octyloxy]-6-hydroxymethyl pyridine, that is to say, the compound of the following structure:




is disclosed as an important intermediate compound. However, the known procedure for the preparation of this type of compound is not ideally suited to large scale application. The object of the present invention is to provide an alternative process for the preparation of such intermediates which is suitable for large scale commercial use.

The present invention therefore provides, in a first aspect, a process for the preparation of a compound of formula (I) or a salt or N-oxide thereof:



in which

R<sup>1</sup> is hydrogen, benzyl or a group of formula (A):




in which n is 1 to 20; and

R<sup>5</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy or trifluoromethyl;


$R^2$  and  $R^3$  are independently hydrogen or  $C_{1-6}$ alkyl;  
 $R^4$  is cyano or  $CO_2R^6$  where  $R^6$  is hydrogen or  $C_{1-6}$ alkyl; and  
 the dotted line represents an optional double bond;  
 which process comprises coupling a compound of formula (II):

5



(II)

- 10 in which  $R^1$  is as defined in formula (I) and  $R^7$  is a leaving group, with a compound of formula (III) or a salt thereof:



(III)

15

in which  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (I) in the presence of an organometallic catalyst, and optionally thereafter:

- converting the resulting compound of formula (I) into a further compound of formula
- 20 (I)
- forming a salt or N-oxide.

Suitable organometallic catalysts include, for example, palladium catalysts. Those skilled in the art will appreciate that palladium catalysts can, if desired, be formed *in situ*. The processes of the invention can be carried out using pre-prepared catalysts or catalysts formed *in situ*. Preferred catalysts are palladium (II) catalysts such as  $Pd(OAc)_2$ ,  $Pd(OAc)_2/(o-tol)_3P$ ,  $Pd(OAc)_2/Ph_3P$ ,  $Pd(OAc)_2/tri(2-furyl)phosphine$ ,  $(Ph_3P)_2PdCl_2$  and  $PdCl_2/Ph_3P$ .

- 30 Preferably  $R^1$  is a group of formula (A) where  $R^5$  is  $C_{1-6}$ alkoxy, for example methoxy. When  $R^1$  is a group of formula (A),  $n$  is suitably 1 to 20, preferably  $n$  is 2 to 8.

Suitably  $R^2$  and  $R^3$  are hydrogen or  $C_{1-6}$ alkyl, preferably  $R^2$  and  $R^3$  are both hydrogen.

Suitably  $R^4$  is cyano or  $CO_2R^6$  where  $R^6$  is hydrogen or  $C_{1-6}$ alkyl, preferably  $R^4$  is  $CO_2R^6$  where  $R^6$  is  $C_{1-6}$ alkyl such as methyl or butyl.

5 Suitably  $R^7$  is a leaving group such as halogen, OTf or  $OSO_2Ar$  where Ar is an optionally substituted aryl group. Suitable substituents include  $C_{1-6}$ alkyl, for example methyl. Preferably  $R^7$  is halogen, in particular bromo or iodo.

Preferred compounds of formula (I) which can be prepared using the above process include:

- 10 n-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl} propenoate,  
methyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl} propenoate,  
methyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl} propenoate,  
t-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl} propenoate,  
3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl} propenoic acid,  
15 n-butyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl} propenoate,  
ethyl (3-hydroxy-6-methylpyridin-2-yl)propenoate,  
ethyl 3-{3-hydroxy-6-hydroxymethylpyridin-2-yl}propenoate,  
ethyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate,  
n-butyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, and  
20 methyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate,  
and salts and N-oxides thereof.

The coupling reaction is carried out in a suitable solvent, preferably at elevated temperature. Preferably the coupling reaction is carried out in DMF, in particular aqueous  
25 DMF, at a temperature of about 80 to about 160°C, preferably at about 120°C.


The term 'salts' in relation to compounds of formula (III) refers to carboxylate salts of compounds of formula (III), in which  $R^4$  is  $CO_2^{\ominus}M^{\oplus}$  where M is a metal ion such as sodium or potassium. Examples of such compounds include potassium acrylate.

30

Salts of compounds of formula (I) can be prepared by treatment with an inorganic or organic acid, or when  $R^4$  is  $CO_2H$ , by treatment with an inorganic or organic base. N-oxides of the pyridyl nitrogen can be prepared using standard techniques.

35 Compounds of formulae (II) and (III) are commercially available or can be prepared using standard procedures well known to those skilled in the art.

For example, compounds of formula (II) in which  $R^1$  is a group of formula (A) can be prepared by reaction of a compound of formula (II) in which  $R^1$  is hydrogen with a compound of formula (IV):



(IV)

in which  $n$  and  $R^5$  are as defined in formula (II) and  $X$  is a leaving group.

10


Suitably leaving groups  $X$  include, for example, halo,  $C_{1-6}$ alkyl $SO_2$  such as methanesulphonyl or  $ArSO_2$  where  $Ar$  is optionally substituted phenyl, for example  $p$ -toluenesulphonyl. Preferably  $X$  is halo or  $p$ -toluenesulphonyl. Compounds of formula (II) in which  $R^1$  is hydrogen can be reacted with compounds of formula (IV) in the presence of a suitable base in an inert solvent, preferably at elevated temperature. For example, the reaction can be carried out using potassium or sodium carbonate in DMF at elevated temperatures

15

Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures. For example a compound of formula (I) in which  $R^1$  is benzyl may be converted into a compound of formula (I) in which  $R^1$  is hydrogen by hydrogenation. A compound of formula (I) in which  $R^1$  is hydrogen can be reacted with a compound of formula (IV) under conditions described above to give a compound of formula (I) in which  $R^1$  is a group of formula (A). Compounds of formula (I) in which  $R^4$  is  $CO_2R^6$  where  $R^6$  is  $C_{1-6}$ alkyl can be converted into compounds of formula (I) in which  $R^4$  is  $CO_2H$  using standard ester hydrolysis procedures. Compounds of formula (I) in which the dotted line represents a double bond, that is to say forming a group  $CR^2=CR^3-R^4$ , can be converted to the corresponding saturated compounds having the group  $CHR^2-CHR^3-R^4$  by hydrogenation.

25  
30


As mentioned above, compounds of formula (I) are intermediates for the preparation of medicaments. In a further aspect, the present invention therefore provides a process for the preparation of a compound of formula (IA) or a salt or N-oxide thereof:



(IA)

5 in which:

$R^1$  is hydrogen, benzyl or a group of formula (A):



(A)


10

where  $n$  is 1 to 20 and  $R^5$  is hydrogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy or trifluoromethyl;  
 $m$  is 0 to 5;

$R^8$  and  $R^9$  are independently hydrogen, halogen,  $CO_2H$ ,  $C_{1-6}$ alkyl or  
 $C_{1-6}$ alkoxy; and

15  $R^{10}$  is a group  $CR^2=CR^3-R^4$  or  $CHR^2-CHR^3-R^4$  where  $R^2$  and  $R^3$  are independently  
hydrogen or  $C_{1-6}$ alkyl and  $R^4$  is cyano or  $CO_2R^6$  where  $R^6$  is hydrogen or  $C_{1-6}$ alkyl,  
which process comprises:


coupling a compound of formula (II):



20

(II)


25 in which  $R^1$  is as defined in formula (IA) and  $R^7$  is a leaving group with a compound of  
formula (III) or a salt thereof:



(III)

in which  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (IA)

in the presence of an organometallic catalyst, to give a compound of formula (I):




5

in which R¹, R², R³ and R⁴ are as defined in formula (IA), and thereafter:

- converting the compound of formula (I) into a compound of formula (IA)
- optionally converting a compound of formula (IA) into another compound of formula (IA)
- 10 • optionally forming a pharmaceutically acceptable salt or N-oxide.

Preferred substituents and conditions for the preparation of compounds of formula (I) are the same as those indicated above.


- 15 A compound compound of formula (I) can be converted into a compound of formula (IA) by initially converting the compound of formula (I) into a compound of formula (V):



(V)

20

in which R¹ and R¹⁰ are as defined in formula (IA) and Z is a leaving group, and thereafter reacting the compound of formula (V) with a compound of formula (VI)



(VI)

25

in which R⁴, R⁵ and m are as defined in formula (IA).



In compounds of formula (V) Z is a suitable leaving group, for example those leaving groups defined above for X. Preferably Z is halo, in particular chloro.

5 Compounds of formula (V) can be coupled with compounds of formula (VI) under standard conditions, for example in the presence of a base such as potassium carbonate in an inert solvent or aqueous sodium hydroxide in an inert solvent such as THF/methanol.

10 Compounds of formula (V) and (VI) can be prepared using standard procedures. For example a compound of formula (V) in which Z is halo and  $R^{10}$  is  $CR^2=CR^3-R^4$  can be prepared by treating a compound of formula (I) with a halogenating agent such as thionyl chloride. When  $R^{10}$  is a group  $CR^2=CR^3-R^4$  this may first be reduced to a group  $CHR^2-R^3-R^4$  by hydrogenation in the presence of a suitable catalyst, or by treating with magnesium in methanol, preferably before introduction of the leaving group Z and subsequent coupling

15

Compounds of formula (IA) can be converted into other compounds of formula (IA) using standard chemistry. For example a compound of formula (IA) in which  $R^{10}$  is  $CR^2=CR^3-R^4$  can be converted into a compound of formula (IA) in which  $R^{10}$  is  $CHR^2-CHR^3-R^4$  by hydrogenation. Compounds of formula (IA) in which  $R^1$  is hydrogen or benzyl can be converted to compounds of formula (IA) in which  $R^1$  is a group of formula (A) by reaction with a compound of formula (IV) under conditions described above.

25 It will be appreciated that for use in medicine a salt of a compound (IA) should be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, methanesulphonate or similar pharmaceutically acceptable inorganic or organic acid addition salts.

30 Other non-pharmaceutically acceptable salts may be used for example in the isolation of intermediate or final products and are included within the scope of this invention. When  $R^4$  is  $CO_2H$ , salts can be prepared by treatment with an inorganic or organic base. For compounds which do not possess a sulphur group, N-oxides of the pyridyl nitrogen can be prepared using standard techniques.

35 Particularly preferred compounds of formula (IA) which can be prepared using the above process include 3[2-thia-3-[2-(E-2-carboxyethenyl)-3-[8-(4-methoxyphenyl)octyloxy]-6-pyridyl]propyl]benzoic acid, [[1-thia-2-[6-(2-carboxyethyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6-dichlorobenzene and [[1-thia-2-[6-(E-2-carboxyethenyl)-5-

phenylethyloxy-2-pyridyl]]ethyl]-2,6-dichlorobenzene or pharmaceutically acceptable salts or N-oxides thereof.

Certain compounds of formulae (II) and (V) are themselves believed to be novel and form  
5 a further aspect of the invention.

The following examples serve to illustrate the invention.

**Example 1****n-Butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]  
pyridin-2-yl} propenoate**

5

**(a) 2-Bromo-3-hydroxypyridine<sup>1</sup>**

Bromine (2.74 ml, 8.49 g, 5.31 mmol) was added to 10% sodium hydroxide solution (50 ml) at 5-10°C. This hypobromite solution was added over 20 min to a solution of 3-hydroxypyridine (5.0 g, 52.6 mmol) in 10% sodium hydroxide (50 ml). The mixture was stirred an additional 30 min. Acetic acid was added to bring the pH of the solution to between pH 6 and pH 7. The mixture was cooled to 5°C for 1 h and the product filtered off. It was washed with water and dried in vacuum at 85°C to give the product (6.22 g, 67%).

15 Reference:

1) G J Clark & L W Deedy, Australian J Chem, (1981), 34, 927

**(b) 1-Bromo-8-chlorooctane**

1,8-Octanediol (72 g, 0.5 mmol), toluene (1 L) and 48% hydrobromic acid (110 g, 0.65 mol) were heated to reflux and water azeotropically removed. The solution was cooled to 60°C, extracted with 10% hydrochloric acid (3 x 300 ml) and redried by azeotropic distillation. DMF (2.5 ml) was added, the mixture heated to 75°C and thionyl chloride (55.6 g, 0.47 mol) added over 10 min such that this temperature was maintained. The temperature was raised to 85-90°C for 1 h and the reaction checked by GC for unreacted 1-bromooctan-8-ol (in this case found to be 1.9% by PAR). The mixture was cooled to 80°C and washed successively with 10% sodium hydroxide solution (2 x 200 ml) and water (2 x 300 ml, 1 x 400 ml). Toluene (550 ml) was removed by distillation to leave 259.2 g of solution containing 1-bromo-8-chlorooctane. This was used directly in the reaction with anisylmagnesium bromide. The yield can be calculated by GC assay against an internal standard or by chlorine analysis. Typically it is in the range 80-85%.

25  
30**(c) Anisylmagnesium Bromide**

Magnesium (36 g, 1.5 mol), iodine (a few crystals) and THF (1 L) were heated under nitrogen, with stirring, at reflux for 15 min. The mixture was cooled to 20°C, stirring stopped, and 1,2-dibromoethane (2.5 ml) added. After an exothermic reaction was observed (a few min) stirring was restarted which was

35

accompanied by a rise in temperature to 35°C. The mixture was cooled to 20°C and 4-bromoanisole slowly added over 1 h at 14-18°C with cooling. Stirring was continued for 10 min after the addition was complete.

- 5 The solution was assayed (HPLC) after an aqueous quench which gave a molarity of 0.88. Alternatively it can be titrated against sec-butanol in xylene using 1,10-phenanthroline as indicator.

(d) 1-Chloro-8-(4-methoxyphenyl)-octane

10

- Bromochlorooctane in toluene (256 g containing approx 95.3 g, 0.42 mol), lithium tetrachlorocuprate in THF (33 ml of 1 mol solution) and THF (46 ml) were heated to reflux (98°C) under nitrogen. Anisylmagnesium bromide solution (0.75 L) was added over 10 min such that a vigorous reflux was maintained. Reflux was continued (78°C, 1 h) until no bromochlorooctane remained by GC analysis. The mixture was cooled to 20°C and 10% ammonium chloride solution (0.5 L) added (cooling required). After phase separation the organic phase was further washed with ammonium chloride solution (0.5L) and saturated sodium chloride solution (3 x 0.5 L). The organic solution was dried over magnesium sulphate, filtered, and the solvent removed under reduced pressure to leave 124.9 g of crude product. This was distilled (178-205°C, 3 mb) to give 72.1 g containing 59.7 g on assay. This represents a yield of 46.4% from octanediol.

(e) 2-Bromo-3-hydroxy-6-hydroxymethylpyridine

- 25 Potassium hydroxide (85% assay, 113.8 g, 1.73 mol) was dissolved in distilled water (750 ml) and to the solution was added 2-bromo-3-hydroxypyridine (300 g, 1.72 mol), ethylenediaminetetraacetic acid sodium salt (2 mol%, 13.1 g, 0.034 mol) and formalin (37-41% w/v 470 ml, 5.95 mol). The stirred mixture was heated at 90-95°C until the assay (HPLC) of remaining starting material fell below 3% (approx 5 h). The reaction mixture was then cooled to room temperature and glacial acetic acid (103 ml) added and stirred for a further 2h. The precipitated solid was filtered from the mixture and the filtrate saturated with sodium chloride (310 g). The resulting solution was extracted with ethyl acetate (4 x 280ml). The combined organic extracts were dried and evaporated to dryness keeping the temperature below 85°C. The residue was assayed by HPLC to determine the quantity of contained 2-bromo-3-hydroxy-6-hydroxymethylpyridine. The yield was typically 65%.

The quantities of materials used in the alkylation reaction are based on the assay.

5      **(f) 2-Bromo-6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridine hydrobromide**

The crude 2-bromo-3-hydroxy-6-hydroxymethylpyridine (vide supra, 1.12 mol) was dissolved in dimethyl formamide (1150 ml) at 60°C. 1-Chloro-8-(4-anisyl)-octane (342 g, 1.34 mol) and potassium carbonate (388 g, 2.81 mol) were added. It was found to be  
10      important that the potassium carbonate was ground to as fine a powder as possible.

The mixture was stirred vigorously and heated to 90-95°C until the assay of 2-bromo-3-hydroxy-6-hydroxymethylpyridine (by HPLC) fell below 3% (approx 5h). The mixture was then cooled to room temperature, poured into water (10 L) and extracted  
15      with ethyl acetate (3 x 670 ml). The combined ethyl acetate extracts were washed with water (2 x 500 ml) and dried before being evaporated to dryness.

The crude reaction product was dissolved in butan-1-ol (2700 ml) and hydrogen bromide gas (120 g) passed through the solution keeping the temperature below 70°C. After allowing the mixture to cool to 10°C with vigorous stirring the  
20      solid product was filtered and washed with ethyl acetate (2 x 500 ml). The solid product was dried under vacuum at 60°C for 4 days. Yield 421 g, 75%.

25      **(g) n-Butyl 3-(6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl) propenoate**

2-Bromo-6-hydroxymethyl-3[8(4-methoxyphenyl)octyloxy]pyridine (5.01 g, 11.9mmol), tetra-n-butylammonium iodide (4.38 g, 11.9 mmol), potassium acetate (3.01 g, 30.7mmol), bis(triphenylphosphine)palladium dichloride (0.33 g, 0.5 mmol) DMF (23ml), water (1.2ml) and n-butyl acrylate (3.4 ml, 3.05 g, 23.8  
30      mmol) were placed under nitrogen by repeated evacuation and filling of the flask. The mixture was stirred and heated at 120°C until starting material was consumed (HPLC), typically 2-8h. The reaction mix was cooled and poured into water (250 ml). The product was extracted into ethyl acetate (3 x 80 ml) and the combined extracts were washed with water (3 x 60 ml). The organic layer was dried  
35      over sodium sulphate and evaporated. The residue was purified by flash column chromatography to give the product as an oil, 4.17g, 75%.

**Example 2****n-Butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl) octyloxy]pyridin-2-yl}propenoate hydrochloride**

5

To a solution of 6-hydroxymethyl-2-iodo-3-[8(4-methoxyphenyl)octyloxy]pyridine (2.34 g, 5.0 mmol) in DMF (9.5 ml) and water (0.5 ml) were added potassium acetate (1.23 g, 12.5 mmol), palladium acetate (45 mg, 0.2 mmol) and n-butyl acrylate (2.16 ml, 192 g, 15 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 50 min. The mixture was cooled and added to water (60 ml). The product was extracted into ethyl acetate (3 x 20 ml) and the combined extracts washed with water (10 ml) and 5% sodium chloride solution (2x10 ml). The extracts were dried and evaporated. The residue was taken up in n-butanol (20ml) and warmed to 50°C. Hydrogen chloride was passed into the solution, which was then cooled to 5°C. The product (as hydrochloride) was filtered, washed with n-butanol and ethyl acetate and dried (1.45 g, 57%).  
mp 152-154°C

10

15

**NMR  $\delta$  (CDCl<sub>3</sub>):**

0.97 (2H, t, J = 7 Hz); 1.1-1.95 (16 H, m); 2.55 (2H, t, J = 7 Hz); 3.77 (3H, s); 3.91 (1H, t, J = 5 Hz, OH); 4.00 (2H, t, J = 7 Hz); 4.21 (2H, t, J = 7 Hz); 4.69(2H, d, J = 5Hz); 6.83 (2H, d, J = 7 Hz); 6.95-7.4 (5H, m); 8.08 (1H, d, J= 15Hz).

20

**Example 3**

25

**Methyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoate**

30

Following the procedure outlined in Example 1(g), 2-Bromo-6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridine was treated with an equivalent amount of methyl acrylate to give methyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl) octyloxy]pyridin-2-yl} propenoate in similar yield. The methyl ester solidifies on standing.

**Example 4****Methyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoate hydrochloride**

5 2-Bromo-6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridine (19.8 g, 46.9mmol) was dissolved in DMF (90.3 g) and to the solution were added potassium acetate (11.55 g, 118.0 mmol), tetra-n-butylammonium iodide (17.38 g, 47.0 mmol), bis(triphenylphosphine)palladium dichloride (1.32 g, 1.88 mmol) and methyl  
10 acrylate (12.20 g, 142.0 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 24 h. The mix was added to water (500 ml). The product was extracted into ethyl acetate (2 x 200 ml). The combined extracts were washed with water (2 x 200 ml), dried and evaporated to leave an oil (28.7 g). This residue was taken up in 2-propanol (230 ml) and filtered from insoluble material. The filtrate was treated with a  
15 solution of hydrogen chloride in methanol (9% w/w; about 19 ml) to precipitate the product as its hydrochloride (16.88 g, 67%).  
mp 136-140°C

NMR  $\delta$  (CDCl<sub>3</sub>):

20 1.1-1.7 (10H, m); 1.91 (2H, quin, J = 7 Hz); 2.54 (2H, t, J = 7 Hz); 3.79 (3H, s); 3.84 (3H, s); 5.03 (2H, s); 6.82 (2H, d, J = 7 Hz); 7.11 (2H, d, J = 7 Hz); 7.67(1H, d, J = 15 Hz); 7.84 (2H, m); 8.11 (1H, d, J = 15 Hz).

**Example 5**

25 **t-Butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoate**

To a solution of 2-bromo-6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridine (5.00 g, 11.8 mmol) in DMF (22.8 ml) and water (1.2 ml) were added potassium acetate  
30 (3.00 g, 30.6 mmol), tetra-n-butylammonium iodide (4.36 g, 11.8 mmol), bis(triphenylphosphine)palladium dichloride (0.33 g, 0.47 mmol) and t-butyl acrylate (6.16 g, 48 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 45 min. The mixture was cooled and added to water (250 ml). The product was extracted into ethyl acetate (2 x 60 ml). The combined extracts were washed with  
35 water (100 ml), 5% sodium chloride solution (2 x 100 ml), then dried and evaporated. The product was obtained by flash column chromatography using silica and 10% ether in dichloromethane. Yield 4.29 g, 77%.

**Example 6****3-{6-Hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoic Acid**

## 5 a) Using acrylic acid

To a solution of 2-bromo-6-hydroxymethyl-[8(4-methoxyphenyl)octyloxy]pyridine (5.00 g, 11.8 mmol) in DMF (22.8 ml) and water (1.2 ml) were added potassium acetate (2.91 g, 29.7 mmol), tetra-n-butyl ammonium iodide (4.37 g, 11.8 mmol),  
10 bis(triphenylphosphine)palladium dichloride (0.33 g, 0.47 mmol) and acrylic acid (2.55 g, 35.4 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 5.5 h. The mix was cooled, solids filtered and washed with ethyl acetate (100 ml). The filtrate was washed with water (250 ml, 2 x 125 ml), dried and evaporated to leave a solid. Pure product was obtained by flash column chromatography (silica, 20% ether in  
15 dichloromethane) (3.28 g, 67%).

## b) Using potassium acrylate

To a solution of 2-bromo-6-hydroxymethyl-[8(4-methoxyphenyl)octyloxy]pyridine  
20 (5.00 g, 11.8 mmol) in DMF (22.8 ml) and water (1.2 ml) were added potassium acetate (2.91 g, 29.7 mmol), tetra-n-butylammonium iodide (4.37 g, 11.8 mmol), triphenylphosphine (0.245 g, 0.94 mmol), palladium chloride (83 mg, 0.47 mmol) and potassium acrylate (3.91 g, 35.4 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 3.3 h. Some potassium acrylate remained undissolved.  
25 The mixture was cooled, solids filtered and washed with ethyl acetate (2 x 60 ml). The filtrate was washed with water (250 ml) and with 5% sodium chloride solution (2 x 125 ml). The organic layer was dried and evaporated. The pure product was obtained by flash column chromatography (silica, 20% ether in dichloromethane) (3.52 g, 72%). mp 112-114°C.

30

NMR  $\delta$  (CDCl<sub>3</sub>):

1.1-1.7 (10H, m); 1.83 (2H, quin, J = 7 Hz); 2.62 (2H, t, J = 7 Hz); 3.77 (3H, s); 4.00 (2H, t, J = 7 Hz); 4.70 (2H, s); 6.80 (2H, d, J = 7 Hz); 7.0-7.3 (5H, m); 8.17 (1H, d, J = 14 Hz).



**Example 7****n-Butyl 3-(6-hydroxymethyl-3-(phenethyloxy)pyridin-2-yl)propenoate**

5

To a solution of 2-bromo-6-hydroxymethyl-3-phenethyloxypyridine (1.33 g, 4.32mmol) in DMF (4.75 ml) and water (0.25 ml) were added potassium acetate (1.23 g, 5.13 mmol), tetra-n-butyl ammonium iodide (1.89 g, 5.13 mmol), bis(triphenylphosphine)palladium dichloride (0.144 g, 0.205 mmol) and n-butyl acrylate (1.48 ml, 1.31 g, 10.3 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 21 h. The mixture was cooled and poured into water (60ml). The product was extracted into ethyl acetate (3 x 20 ml). The combined extracts were washed with water, dried and evaporated. The residue was purified by flash column chromatography eluting with ether to give the product (1.24 g, 81%). mp (B.HCl) 180-185°C.

15

NMR  $\delta$  (CDCl<sub>3</sub>):

0.98 (3H, t, J = 7 Hz); 1.46 (2H, sx, J = 7 Hz); 1.72 (2H, quin, J = 7 Hz); 3.18(2H, t, J = 7 Hz); 3.6 (1H, broad t); 4.25 (4H, overlapping t's); 4.70 (2H, broad d); 7.04 (1H, d, J = 15 Hz); 7.1-7.4 (7H, m); 8.10 (1H, d, J = 15 Hz).

20

**Example 8****Ethyl (3-hydroxy-6-methylpyridin-2-yl)propenoate**

25

To a solution of 3-hydroxy-2-iodo-6-methylpyridine (1.175 g, 5.0 mmol) in DMF (9.5 ml) and water (0.5 ml) were added potassium acetate (1.23 g, 12.5 mmol), triphenylphosphine (105 mg, 0.40 mmol), palladium chloride (36 mg, 0.20 mmol) and ethyl acrylate (1.63 ml, 1.50 g, 15.0 mmol). The mixture was placed under nitrogen and heated at 120°C for 1.5 h. The mixture was cooled, filtered from deposited palladium black, and added to water (100 ml). The product was extracted into ethyl acetate (3 x 30 ml). The combined extracts were washed with water (2x25 ml) and with brine (25 ml), then dried over sodium sulphate and evaporated. This left a tan solid, the product (951 mg, 91%). mp 192-195°C (dec)

30

35

NMR  $\delta$  (d<sup>6</sup>-DMSO, 40°):

1.15 (3H, t J = 7 Hz); 2.38 (3H, s); 3.25 (1H, s, OH); 4.20 (2H, q, J = 7 Hz); 6.80(1H, d, J = 16 Hz); 7.1-7.2 (2H, m); 7.90 (1H, d, J = 16 Hz).

**Example 9****Ethyl 3-{3-hydroxy-6-hydroxymethylpyridin-2-yl}propenoate**

5

To a solution of 3-hydroxy-6-hydroxymethyl-2-iodopyridine (708 mg, 2.82 mmol) in DMF (5.7 ml) and water (0.3 ml) were added potassium acetate (0.74 g, 7.5 mmol), triphenylphosphine (63 mg, 0.24 mmol), ethyl acrylate (0.98 ml, 9.0 mmol) and palladium acetate (27 mg, 0.12 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 5 h. The mix was cooled and poured into water (50 ml). The product was extracted into ethyl acetate (3x20ml) and the combined extracts were washed with water (2 x 15 ml) with brine (15 ml), dried and evaporated. The crude product was purified by passage in ethyl acetate through a pad of silica, yielding after evaporation a yellow solid (295g, 47%). mp (B.HCl) 199-203°C.

15

NMR  $\delta$  (B.HCl) ( $d_6$ -DMSO, 40°):

1.26 (3H, t, J = 7 Hz); 4.23 (2H, q, J = 7 Hz); 4.63 (2H, s); 7.10 (1H, d, J=16Hz); 7.61 (1H, d, J = 8 Hz); 7.81 (1H, d, J = 8 Hz); 7.94 (1H, d, J=16Hz).

20 **Example 10****Ethyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate**

a) From 3-benzyloxy-2-bromo-6-hydroxymethylpyridine

25

To a solution of 3-benzyloxy-2-bromo-6-hydroxymethylpyridine (5.00 g, 17.0 mmol) in DMF (32.3 ml) and water (1.7 ml) were added potassium acetate (4.17 g, 42.5 mmol), tetra-n-butylammonium iodide (6.27 g, 17.0 mmol), bis-(triphenylphosphine)palladium dichloride (0.48 g, 0.68 mmol) and ethyl acrylate (5.53 ml, 5.1 g, 51.0 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 5 h. The reaction mix was cooled and poured into water (300 ml). The product was extracted into ethyl acetate (3 x 50 ml). The combined extracts were washed with water (3 x 40 ml) and with brine. Anhydrous sodium sulphate and charcoal (0.5 g) were added to the organic solution and stirred for 15 min. The solution was filtered and the filtrate evaporated. The residue was dissolved in toluene (12 ml) at 80°C and hexane (6 ml) added at the same temperature. The solution was cooled to 0°C. The crystalline product was filtered off, washed with 1:1 toluene : hexane (10 ml) and dried. The yield was 4.20 g, 79%. mp 106-108°C.

35

NMR  $\delta$  (CDCl<sub>3</sub>):

1.35 (3H, t, J = 7 Hz); 3.60 (1H, broad s); 4.26 (2H, q, J = 7 Hz); 4.70 (2H, broad s); 5.18 (2H, s); 7.05 (1H, d, J = 16 Hz); 7.1-7.45 (7H, m); 8.16 (1H, s, J = 16 Hz).

b) From 3-benzyloxy-6-hydroxymethyl-2-iodopyridine

To a solution of 3-benzyloxy-6-hydroxymethyl-2-iodopyridine (1.20 g, 3.50 mmol) in DMF (6.4 ml) and water (0.32 ml) were added potassium acetate (0.83 g, 8.5 mmol) palladium acetate (32 mg, 0.14 mmol) and ethyl acrylate (1.1 ml, 1.01 g, 10 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 1.25 h. By hplc the solution yield was 62%.

NMR  $\delta$  (CDCl<sub>3</sub>):

0.97 (3H, t, J = 7 Hz); 1.44 (2H, sx, J = 7 Hz); 1.68 (2H, m, J = 7 Hz); 3.60 (1H, broad t), 4.20 (2H, t, J = 7 Hz); 4.67 (2H, broad d); 5.16 (2H, s); 7.04 (1H, d, J = 16 Hz); 7.1-7.45 (m, 7H); 8.16 (1H, d, J = 16 Hz).

### Example 11

#### n-Butyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate

To a solution of 2-bromo-3-benzyloxy-6-hydroxymethylpyridine (2.94 g, 10.0 mmol) in DMF (19 ml) and water (1 ml) were added potassium acetate (2.45 g, 25.0 mmol), tetra-n-butylammonium iodide (3.69 g, 10.0 mmol), bis(triphenylphosphine)palladium dichloride (281 mg, 0.4 mmol) and n-butyl acrylate (4.31 ml, 3.84 g, 30 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 3 h. The mixture was cooled and poured into water (180 ml). The product was extracted into ethyl acetate (3 x 30 ml). The combined extracts were washed with water (3 x 25 ml), dried and evaporated. This residue was purified by flash column chromatography, eluting with a gradient of ethyl acetate in dichloromethane to isolate the product, an oil (2.72 g, 80%).

NMR  $\delta$  (CDCl<sub>3</sub>):

0.97 (3H, t, J = 7 Hz); 1.44 (2H, sx, J = 7 Hz); 1.68 (2H, m, J = 7 Hz); 3.60 (1H, broad t), 4.20 (2H, t, J = 7 Hz); 4.67 (2H, broad d); 5.16 (2H, s); 7.04 (1H, d, J = 16 Hz); 7.1-7.45 (m, 7H); 8.16 (1H, d, J = 16 Hz).

**Example 12****Methyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate**

5 To a solution of 2-bromo-3-benzyloxy-6-hydroxymethylpyridine (2.94 g, 10mmol) in DMF (19 ml) and water (1 ml) were added potassium acetate (2.45 g, 10.0 mmol), tetra-n-butylammonium iodide (3.69 g, 10.0 mmol), bis(triphenyl-phosphine)palladium dichloride (281 mg, 0.4 mmol) and methyl acrylate (2.70 ml, 2.58 g, 30 mmol). The mixture was placed under nitrogen and stirred and heated at 120°C for 5 h. The mixture was cooled  
10 and added to water (180 ml). The product was extracted into ethyl acetate (3 x 30 ml). The combined extracts were washed with water (3 x 25 ml), dried and evaporated. The residue was purified by flash column chromatography eluting with dichloromethane, then 4:1 dichloromethane :ethyl acetate to give the product (2.516 g, 84%).

15 NMR  $\delta$  (CDCl<sub>3</sub>):  
3.80 (3H, s); 4.70 (2H, s); 5.16 (2H, s); 7.05 (1H, d, J = 16 Hz); 7.1-7.45 (7H, m); 8.16 (1H, d, J = 16 Hz).

**Example 13**

20

**n-Butyl 3-(6-Hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl)propenoate**

2-Bromo-6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridine hydro-bromide  
25 (10.0 kg, 19.87 mol) was added to a solution of sodium hydroxide (0.82kg, 20.5 mol) in demineralised water (16.4 L), mixed with ethyl acetate (54.7 kg). The mixture was stirred for 15 min and the phases separated. The aqueous phase was washed with ethyl acetate (6.1 kg). The bulked organic solutions were washed with demineralised water (11.4 L). The mixture was heated to reflux under 'Dean and Stark' conditions until 0.3 L of water  
30 had been collected. Solvent (45.0 L) was removed by distillation at atmospheric pressure. Dimethyl formamide (50.0 kg) was added and distillation continued under low vacuum to remove a further 37.0 L of solvent. The mixture was cooled to 20°C. Potassium acetate (4.50 kg, 45.85 mol) was added, followed by tetra-n-butylammonium iodide (6.75 kg, 18.27 mol).

35

Triphenylphosphine (0.4177 kg, 1.59 mol) and palladium dichloride (0.1412 kg, 0.89 mol) were stirred in dimethylformamide (4.0 kg) to form bis(triphenyl

phosphine)palladium dichloride. This mixture was added to the reaction solution followed by n-butyl acrylate (7.02 kg, 54.77 mol) and demineralised water (2.0 L).

5 The mixture was heated to 120-125°C and stirred at this temperature for 3.75 h under a slight nitrogen pressure (100 mb).

The mixture was cooled to 20°C and filtered. The filtrate was added to a mixture of demineralised water (386.0 L) and ethyl acetate (41.0 kg). The filter was washed with ethyl acetate (30.5 kg) and the wash added to the solution. The mixture was stirred for 15  
10 min and the phases separated. The aqueous phase was washed with ethyl acetate (28.7 kg). The organic phases were combined and washed with demineralised water (3 x 22.7 L).

The organic solution was heated to reflux under 'Dean and Stark' conditions to remove  
15 residual water. Solvent (20.0 L) was removed by distillation at atmospheric pressure. n-Butanol (16.2 kg) was added. Solvent was removed in 10.0 L portions by distillation at atmospheric pressure, the volume being maintained by the addition of n-butanol in 10.0 L portions until 50.0 L of solvent had been removed and a solution temperature of 117°C was attained. The solution was cooled to 10°C and stirred at this temperature for 9 h and  
20 55 min. The solution was filtered through a 1 micron filter. The filter and transfer lines were washed with n-butanol (3.7 kg) and the wash added to the bulk.

The solution was heated to 65°C and gaseous hydrogen chloride (1.5 kg, 41.14mol) was added over 5 min allowing the temperature to rise to 80°C. The mixture was heated to  
25 90°C to complete solution. the mixture was cooled to 20°C over 3 h and 10 min, then to 5°C, and stirred at 5°C for 1 h. The product was isolated by centrifugation, washed twice with ethyl acetate (1 x 17.8 kg, 1x13.4kg), then dried in an atmospheric tray drier for 18 h at 50°C to give a yield of 7.5 kg at 97.12% purity (7.28 kg at 100%).

#### 30 Example 14


**3-{2-Thia-[(2-(E)-2-carboxyethenyl)-3-[8-(4-methoxy-phenyl)octyloxy]-6-pyridyl]propylbenzoic Acid**

35 n-Butyl-3-{6-hydroxymethyl-3-[8-(4-methoxyphenyl)octyloxy]pyridin-2-yl}-propenoate hydrochloride (4.0 kg, assumed to be 100%, 7.9 mol) was mixed with dichloromethane (24.6 kg). Thionyl chloride (2.66 kg, 22.4 mol) was added over 15 min maintaining the temperature at 20-25°C. The mixture was stirred at 20-25°C for 3 h. The organic solution

- was added over 15 min to a solution of sodium carbonate (4.0 kg at 99.28%, 3.97 kg at 100%, 37.46 mol) in demineralised water (40.0 L). Dichloromethane (2.0 kg) was added and the mixture stirred for a further 10 min to give a pH of 7. The phases were allowed to separate for 14.5 h, and the organic phase removed. The aqueous phase was extracted with dichloromethane (10.6 kg) and discarded. The organic phase was washed with demineralised water (8.0 L), then with a solution of sodium chloride (2.5 kg) in demineralised water (8.0 L). Solvent (25.0 L) was removed by distillation at atmospheric pressure maintaining the temperature below 48°C ('concentrate').
- 10 A solution of sodium hydroxide (1.98 kg, 49.5 mol) in demineralised water (4.6 L) was added to methanol (2.64 kg) maintaining the temperature at 20-25°C. The mixture was stirred for 10 min, and methyl m-bromomethylbenzoate (1.54 kg, 8.5mol) was added over 10 min. The mixture was stirred for 40 min to give complete solution ('sodium salt').
- 15 Tetrahydrofuran (7.4 kg) was added to the 'concentrate'. The 'sodium salt' solution was added over 1.25 h, maintaining the temperature at 25-30°C. The mixture was stirred for 2 h and 35 min, then cooled to 15-20°C. Hydrochloric acid (1 M, 32.0 L) was added to the mixture over 1 hr and 5 min, maintaining the temperature at 15-20°C, to give a pH of 4.5. The product precipitated as an oily solid. The mixture was stirred for 17 h.
- 20 Demineralised water (30.0 L) was added to the mixture to convert the oily product to a crystalline material. The solid was isolated by filtration and washed with demineralised water (5.0 L).
- The wet crude product was added to ethyl acetate (36.0 kg) and water was removed by distillation under 'Dean and Stark' conditions. Solvent was removed by distillation at atmospheric pressure, the volume being maintained by the addition of ethyl acetate in 4.0 L portions until 25.2 kg had been added. The mixture was stirred at reflux for 10 min to ensure complete solution.
- 30 The hot solution was filtered through a 1 micron filter, cooled to 20-25°C over 40min, then stirred at this temperature for 1 hr and 5 min. The product was isolated by filtration and washed with ethyl acetate (4.5 kg) to give a wet weight of 5.5 kg. The product was dried in the vacuum tray drier at 50-55°C for 26 h to give a yield of 3.5 kg at 100% (78.5%).


## Claims:

1. A process for the preparation of a compound of formula (I) or a salt or N-oxide thereof:



in which

R¹ is hydrogen, benzyl or a group of formula (A):



in which n is 1 to 20; and


R⁵ is hydrogen, C₁-6alkyl, C₁-6alkoxy or trifluoromethyl;

15 R² and R³ are independently hydrogen or C₁-6alkyl;


R⁴ is cyano or CO₂R⁶ where R⁶ is hydrogen or C₁-6alkyl; and

the dotted line represents an optional double bond;

which process comprises coupling a compound of formula (II):




in which R¹ is as defined in formula (I) and R⁷ is a leaving group, with a compound of  
25 formula (III) or a salt thereof:



in which  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (I) in the presence of an organometallic catalyst, and optionally thereafter:


- converting the resulting compound of formula (I) into a further compound of formula (I)
- forming a salt or N-oxide.

2. A process for the preparation of a compound of formula (IA) or a salt or N-oxide thereof:



15 in which:

$R^1$  is hydrogen, benzyl or a group of formula (A):



20


where  $n$  is 1 to 20 and  $R^5$  is hydrogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy or trifluoromethyl;  
 $m$  is 0 to 5;

$R^8$  and  $R^9$  are independently hydrogen, halogen,  $CO_2H$ ,  $C_{1-6}$ alkyl or  $C_{1-6}$ alkoxy; and

25  $R^{10}$  is a group  $CR^2=CR^3-R^4$  or  $CHR^2-CHR^3-R^4$  where  $R^2$  and  $R^3$  are independently hydrogen or  $C_{1-6}$ alkyl and  $R^4$  is cyano or  $CO_2R^6$  where  $R^6$  is hydrogen or  $C_{1-6}$ alkyl,

which process comprises:

coupling a compound of formula (II):




30

in which  $R^1$  is as defined in formula (IA) and  $R^7$  is a leaving group with a compound of




formula (III) or a salt thereof:



(III)

- 5 in which  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (IA)  
in the presence of an organometallic catalyst, to give a compound of formula (I):



(I)

10

in which  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as defined in formula (IA), and thereafter:

- converting the compound of formula (I) into a compound of formula (IA)
  - optionally converting a compound of formula (IA) into another compound of formula (IA)
  - 15 • optionally forming a pharmaceutically acceptable salt or N-oxide.
3. A process according to claim 1 or 2 in which the catalyst is a palladium derivative.
4. A process according to any one of claims 1 to 3 in which the palladium coupling is  
20 carried out in aqueous DMF.
5. A process according to any one of claims 1 to 4 in which  $R^1$  is a group of formula (A) where n is 2 to 8.
- 25 6. A process according to any one of claims 1 to 5 in which  $R^4$  is  $CO_2R^6$  where  $R^6$  is hydrogen or  $C_{1-6}$ alkyl.
7. A process according to any one of claims 1 to 6 in which  $R^5$  is methoxy.
- 30 8. A process according to claim 1 in which the compound prepared is:  
n-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl} propenoate,  
methyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl} propenoate,  
methyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl} propenoate,


- t-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoate,  
 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoic acid,  
 n-butyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl}propenoate,  
 ethyl (3-hydroxy-6-methylpyridin-2-yl)propenoate,  
 5 ethyl 3-{3-hydroxy-6-hydroxymethylpyridin-2-yl}propenoate,  
 ethyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate,  
 n-butyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate,  
 methyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, and  
 and salts and N-oxides thereof.

10

9. A process according to claim 2 in which the compound of formula (IA) is  
 3[2-thia-3-[2-(E-2-carboxyethenyl-3-[8-(4-methoxyphenyl)octyloxy]-6-  
 pyridyl]propyl]benzoic acid,  
 [[1-thia-2-[6-(2-carboxyethyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6-dichlorobenzene, or  
 15 [[1-thia-2-[6-(E-2-carboxyethenyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6-  
 dichlorobenzene,  
 or pharmaceutically acceptable salts or N-oxides thereof.

10. A compound of formula (II):

20



(II)

- 25 in which R<sup>1</sup> and R<sup>7</sup> are as defined in claim 1.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 94/02028

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 C07D213/65 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 06085 (SMITH-KLINE BEECHAM CORPORATION) 1 April 1993 cited in the application ---	1-10
A	CHEMICAL AND PHARMACEUTICAL BULLETIN., vol.33, no.11, 1985, TOKYO JP pages 4764 - 4768 T. SAKAMOTO ET AL. 'Condensed heteroaromatic ring systems IV.' * preparation of compound 2 * ---	1
A	M.G. DAUBEN 'Organic Reactions Volume 27, Chapter 2' 1982, WILEY, NEW YORK see page 354 - page 356 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* & \* document member of the same patent family

Date of the actual completion of the international search

6 October 1994

Date of mailing of the international search report

25. 10. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

De Jong, B

# INTERNATIONAL SEARCH REPORT

Int. onal Application No  
PCT/EP 94/02028

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF ORGANIC CHEMISTRY., vol.54, no.15, 1989, EASTON US pages 3618 - 3624 E.C. TAYLOR AND G.S.K. WONG 'Convergent and efficient palladium-effected synthesis of DDATHF' * scheme I *	
A	--- JOURNAL OF ORGANIC CHEMISTRY., vol.43, no.15, 1978, EASTON US pages 2947 - 2949 W.C. FRANK ET AL. 'Palladium-catalysed vinylc substitution reactions with heterocyclic bromides' * Table I, 2-bromopyridine *	
A	--- CHEMICAL AND PHARMACEUTICAL BULLETIN., vol.30, no.10, 1982, TOKYO JP pages 3647 - 3656 T. SAKAMOTO ET AL. 'Studies on pyrimidine derivatives.' see table V	
A	--- CHEMICAL AND PHARMACEUTICAL BULLETIN., vol.27, no.1, 1979, TOKYO JP pages 193 - 197 K. EDO ET AL. 'Studies on pyrimidine derivatives.' * preparation of compound 9a *	
P,X	--- DE,A,42 24 402 (SCHERING AKTIENGESELLSCHAFT) 27 January 1994 * page 5, lines 2-3, 58-61 see examples 1B,16H -----	1-9

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 94/02028

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9306085	01-04-93	AP-A- 333	25-04-94
		AU-A- 2573592	27-04-93
		CA-A- 2119467	01-04-93
		CN-A- 1073431	23-06-93
		EP-A- 0604529	06-07-94
		PT-A- 100881	29-10-93
-----			
DE-A-4224402	27-01-94	AU-B- 4415393	14-02-94
		WO-A- 9402464	03-02-94
-----			
4)			